Prognostic scoring accuracy in acute pancreatitis: BISAP versus APACHE II
For predicting severe acute pancreatitis, BISAP demonstrates superior discrimination compared with APACHE II across multiple head-to-head comparisons. [1]
For predicting in-hospital mortality, reported discrimination between BISAP and APACHE II is similar, with some cohorts showing numerically close performance and minimal differences. [2]
Medication Selection Algorithm
Risk stratification accuracy depends on the outcome definition and time window used for scoring. BISAP is calculated using parameters from the early clinical course (notably first 24 hours), which supports early risk discrimination. [2]
APACHE II incorporates acute physiology measures at presentation and ongoing clinical status, which supports mortality discrimination but may not outperform BISAP for “severe disease” definitions used in some studies. [2]
Key Evidence Supporting This Recommendation
Severe disease prediction
-
In a prospective observational cohort of 410 acute pancreatitis admissions, BISAP had higher AUC for severe acute pancreatitis than APACHE II (AUC 0.873 vs 0.761). [1]
-
A multicenter retrospective analysis of 450 patients reported higher AUC for severe disease with BISAP than APACHE II (BISAP AUC 0.91 vs APACHE II AUC 0.84). [3]
In-hospital mortality prediction
-
In a large population-based study, discrimination for in-hospital mortality was close between BISAP and APACHE II (BISAP AUC 0.82 vs APACHE II AUC 0.83). [2]
-
In the 410-patient prospective cohort, BISAP and APACHE II showed comparable AUCs for mortality prediction on comparative analysis (rise in BUN performed similarly to BISAP, and APACHE II was lower than BISAP for mortality-related comparisons in that dataset). [1]
Monotherapy Versus Combination Therapy
Only one question is addressed: prognostic accuracy comparison. No therapeutic combination is involved. BISAP should be selected when the clinical aim is early discrimination of severe disease. [1]
Important Clarifications or Nuances
BISAP includes readily available early variables and has been validated for early mortality identification. [2]
APACHE II may show comparable mortality discrimination but does not consistently outperform BISAP for severe disease outcomes in head-to-head studies. [1]
Initiation Thresholds or Indications
No universally accepted numeric score thresholds for “superiority” are established from the cited head-to-head analyses. Reported performance is therefore best compared by AUC for discrimination in the specific study cohorts. [2], [1]
Common Pitfalls to Avoid
Outcome misclassification can change apparent superiority, because “severe disease” definitions vary across studies, even when both severe and mortality outcomes are measured. [1]
Timing differences in available variables can affect score computation. BISAP is designed for early (first 24-hour) risk assessment, whereas APACHE II depends on physiologic measurements used at scoring. [2]
Target Blood Pressure
No blood pressure targets apply to this prognostic scoring comparison.